1?Enough Cases Clinical Trial
Official title:
Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
1) Observe and compare the curative effect of endostatin/recombined Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced nasopharyngeal darcinoma; 2) Evaluate the security and tolerability in endostatin/recombined Endostatin in alliance with neoadjuvant chemotherapy and Concurrent chemo-radio therapy to treat the local advanced nasopharyngeal darcinoma.
1. experimental group:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 +human
endostatin 7.5mg/m2 iv in day 8-21 and three weeks repeat and total two cycles;followed
by concurrent chemoradiation(Cisplatin 80mg/m2 iv in day 1,21 +human endostatin
7.5mg/m2 iv in day 1-14 and Concurrent Intensity-modulated radiation therapy)
2. Control group:group:docetaxel 75mg/m2 iv in day 1 +Cisplatin 80mg/m2 iv in day 1 and
three weeks repeat and total two cycles;followed by concurrent chemoradiation(Cisplatin
80mg/m2 iv in day 1,21 and Concurrent Intensity-modulated radiation therapy)
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Caregiver), Primary Purpose: Treatment